Central South University is the lead sponsor of 21 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Aripiprazole, Atorvastatin and Escitalopram. The most-studied condition is Schizophrenia.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder
NCT07701616 · ClinicalTrials.gov ↗ · Obsessive-Compulsive Disorder
|
Not applicable | Recruiting | 2026-07 | China |
|
TIS for Improving Cognitive Impairment Associated With Schizophrenia
NCT07446478 · ClinicalTrials.gov ↗ · Cognitive Impairment Associated With Schizophrenia (CIAS)
|
Not applicable | Recruiting | 2026-06 | China |
|
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142 · ClinicalTrials.gov ↗ · Schizophrenia
Drugs: Atorvastatin, Metformin |
Phase 3 | Recruiting | 2025-07 | China |
|
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
NCT06673966 · ClinicalTrials.gov ↗ · Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders
|
Observational | Recruiting | 2025-01 | China |
|
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
NCT07063901 · ClinicalTrials.gov ↗ · Esophagus Cancer
|
Observational | Recruiting | 2025-06 | China |
|
tACS for Working Memory in Schizophrenia
NCT07701343 · ClinicalTrials.gov ↗ · Schizophrenia, Working Memory
|
Not applicable | Recruiting | 2026-07 | China |
|
Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model
NCT06161870 · ClinicalTrials.gov ↗ · Severe Infection
|
Phase 4 | Recruiting | 2021-01 | China |
|
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
NCT07820423 · ClinicalTrials.gov ↗ · Lung Cancer Associated With Cystic Airspaces
|
Observational | Recruiting | 2025-05 | China |
|
Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study
NCT06123897 · ClinicalTrials.gov ↗ · Schizophrenia
|
Observational | Recruiting | 2024-01 | China |
|
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979 · ClinicalTrials.gov ↗ · Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
|
Observational | Recruiting | 2024-08 | China |
|
iTBS for Increased Appetite Induced by Antipsychotics
NCT05783063 · ClinicalTrials.gov ↗ · Schizophrenia
|
Not applicable | Recruiting | 2023-08 | China |
|
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
NCT07066813 · ClinicalTrials.gov ↗ · Lung Cancer Associated With Cystic Airspaces
|
Observational | Recruiting | 2025-06 | China |
|
High Definition Transcranial Direct Current Stimulation of Right Inferior Frontal Gyrus to Improve Social Impairments in Children with Autism
NCT06723522 · ClinicalTrials.gov ↗ · Autism Spectrum Disorder (ASD)
|
Not applicable | Recruiting | 2024-08 | China |
|
Investigating the Insulin Resistance in Individuals With Type 2 Diabetes
NCT06428968 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Not applicable | Recruiting | 2024-09 | China |
|
nTMS for Negative Symptom in Schizophrenia
NCT06642675 · ClinicalTrials.gov ↗ · Schizophrenia
|
Not applicable | Recruiting | 2024-11 | China |
|
TIS for Improving Cognitive Impairment in Schizophrenia
NCT07647380 · ClinicalTrials.gov ↗ · Schizophrenia Disorder, Cognitive Impairments
|
Not applicable | Recruiting | 2026-06 | China |
|
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications
NCT07444463 · ClinicalTrials.gov ↗ · Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD)
|
Not applicable | Not yet open | 2027-01 | China |
|
AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
NCT07593170 · ClinicalTrials.gov ↗ · Obesity, Obese Adolescents, Obese Children and Adolescents
|
Phase 2 | Not yet open | 2026-06 | China |
|
Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder
NCT07648797 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder (GAD)
|
Not applicable | Not yet open | 2026-06 | China |
|
A Correlation Study of Cognitive Function in Patients With Depression
NCT05396989 · ClinicalTrials.gov ↗ · Depression
|
Observational | Not yet open | 2024-05 | China |
|
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
NCT06937476 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD), Rumination
Drugs: Aripiprazole, Escitalopram |
Not applicable | Active, closed | 2025-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 21 | 16 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Central South University is the lead sponsor of 21 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 16 of its 21 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Aripiprazole (1), Atorvastatin (1), Escitalopram (1) and Metformin (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.